comparemela.com

Latest Breaking News On - Chikungunya vaccine - Page 1 : comparemela.com

The first chikungunya vaccine could be a game changer in global health

The FDA s approval of a chikungunya vaccine brings hope to regions facing the highest risk of the mosquito-borne virus that has affected over 110 countries.

United statesIndia generalAnirban mahapatraNational centre for vector borne diseaseDrug administrationValneva austria gmbhSoutheast asiaNorth americaNational centreVector borne disease controlBharat biotechSeparating fact fromHindustan timesWhatsapp channelsFda approvedChikungunya vaccine

US Approves 1st Vaccine Against Chikungunya Virus

US health authorites on Thursday approved the world's first vaccine for chikungunya, a virus spread by infected mosquitoes.

United statesEurope valnevaPeter marksDrug administrationVaccine against chikungunya virusNorth americaChikungunya vaccine

Valneva Reports Positive Safety Data In Adolescents For Chikungunya Vaccine Candidate

Valneva SE (VALN) reported positive initial Phase 3 safety data in adolescents for its single-dose chikungunya virus vaccine candidate VLA1553. The company said the initial safety data generated in the trial VLA1553-321 showed that VLA1553 was generally safe and well tolerated in adolescents aged 12 to 17 years, regardless of previous CHIKV infection.

Juan carlos jaramilloMore such health newsEuropean medicines agencyCarlos jaramilloChief medical officerChikungunya vaccine

Valneva: VLA1553 Takes Lead In Chikungunya Vaccine Race (OTCMKTS:INRLF)

Valneva: VLA1553 Takes Lead In Chikungunya Vaccine Race (OTCMKTS:INRLF)
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

Health canadaBavarian nordicChikungunya vaccineDownload scientific diagramFor approvalFast trackBreakthrough therapy designationsTrial riskCompetition riskManufacturing risk

VLA1553 vaccine candidate for chikungunya disease produces an immune response in a phase 3 trial

The VLA1553 vaccine candidate for chikungunya disease was generally well tolerated and produced an immune response in 99% (263/266) of participants, according to a phase 3 randomized controlled trial published in The Lancet.

United statesDanielle ellisMartina schneiderKatrin dubischarJuan carlos jaramilloKathryn stephensonBeth israel deaconess medical centerVaccine researchClinical strategy managerProgram directorChikungunya vaccineChief medical officerData safety monitoring board

vimarsana © 2020. All Rights Reserved.